Building High-Impact Vendor Partnerships to Accelerate Cell Therapy Execution

• Building phase-appropriate quality systems with defined quality indicators to enable earlystage cell therapy development
• Embedding quality indicators into vendor selection and supplier partnerships to protect execution
• Leveraging quality indicators as strategic tools for risk management and operational agility

Speakers:

Lyndsey Young

Executive Director, Head of Quality

Tr1x therapeutics